MiRNA-based therapy for metabolic diseases: miRNA-142-3p increases muscle mass and the expression of lipolytic genes, and decreases adipose tissue mass via down regulation of its target gene, 28/May/2015, 13.51

MiRNA-based therapy for metabolic diseases: miRNA-142-3p increases muscle mass and the expression of lipolytic genes, and decreases adipose tissue mass via down regulation of its target gene, 28/May/2015, 13.51

MiRNA-based therapy for metabolic diseases: miRNA-142-3p increases muscle mass and the expression of lipolytic genes, and decreases adipose tissue mass via down regulation of its target gene, 28/May/2015, 13.51 150 150 Dr Boomi's Genom-2-Discovery Center

Idea Proposed/Formulated by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, L., MiRNA-based therapy for metabolic diseases: miRNA-142-3p increases muscle mass and the expression of lipolytic genes,  and  decreases adipose tissue mass via down regulation of its target gene, 28/May/2015, 13.51, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Significance: 

This suggests, for the first time, that miRNA-142-3p, by decreasing the expression of its target gene, it may: (1) increase muscle mass; (2) increase the expression of lipolytic genes in adipose tissues; and (3) decrease adipose tissue mass.  Thus, pharmacological formulations encompassing “miRNA-142-3p or its activators“ may be used to treat metabolic diseases, including obesity.

Undisclosed information: How miRNA-142-3p: (1) increase muscle mass; (2) increase lipolytic genes in adipose tissues; and (3) decrease adipose tissue mass

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Share
Start Typing